Weekly Doxorubicin Increases Coronary Arteriolar Wall and Adventitial Thickness

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Eckman, Delrae M ^a   Stacey, R Brandon ^a   Rowe, Robert ^a   D'Agostino, Ralph ^a   Kock, Nancy D ^a   Sane, David C ^b   Torti, Frank M ^a   Yeboah, Joseph ^a   Workman, Susan ^a   Lane, Kimberly S ^a   Hundley, W Gregory ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ADVERSE OUTCOME; ANATOMICAL VARIATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL WALL THICKENING; ARTERIOLE; ARTERY DIAMETER; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CORONARY ARTERY; DISEASE EXACERBATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; HEART INFARCTION; HEART MUSCLE PERFUSION; HISTOPATHOLOGY; LOW DRUG DOSE; MALE; MICROCIRCULATION; NONHUMAN; RAT;

EID: 84874319173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057554     Document Type: Article

References (31)

1. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, et al. (2003) Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21: 3431-3439.
2. Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, et al. (2006) Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin's Lymphoma. Blood 107: 2912-2919.
3. Jensen BV, (2006) Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 33: S15-S21.
4. Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M, (2004) Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A 101: 6975-6980.
5. Kotamraju S, Kalivendi SV, Konorev E, Chitambar CR, Joseph J, et al. (2004) Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis. Methods Enzymol 378: 362-82.
6. L'Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, et al. (2006) DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 291: H1273-H1280.
7. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, et al. (2004) Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279: 8290-8299.
8. Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, et al. (2006) Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 41: 845-854.
9. Lightfoot JC, D'Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, et al. (2010) Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging 3: 550-558.
10. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, et al. (2005) Cardiotoxicity of cancer therapy. J Clin Oncol 23: 7685-7696.
11. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, et al. (2004) Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 22: 820-828.
12. Singal PK, Iliskovic N, (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905.
13. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, et al. (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26: 3777-3784.
14. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, et al. (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and treatment. Circulation 109: 3122-3131.
15. Ferrans VJ, (1978) Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62: 955-961.
16. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, et al. (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease. J Natl Cancer Inst 99: 206-214.
17. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, et al. (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology. J Natl Cancer Inst 102: 14-25.
18. Du XL, Fox EE, Lai D, (2008) Competing causes of death for women with breast cancer and change over time. Am J Clin Oncol 31: 105-116.
19. Heon S, Bernier M, Servant N, Dostanic S, Wang C, et al. (2003) Dexrazoxane does not protect against doxorubicin-induced damage in young rats. Am J Physiol Heart Circ Physiol 285: H499-H506.
20. Csanyi G, Taylor WR, Pagano PJ, (2009) NOX and inflammation in the vascular adventitia. Free Radic Biol Med 47: 1254-1266.
21. Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, et al. (2010) Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res 70: 9287-9297.
22. Barker SG, Talbert A, Cottam S, Baskerville PA, Martin JF, (1993) Arterial intimal hyperplasia after occlusion of the adventitial vasa vasorum in the pig. Arterioscler Thromb13: 70-77.
23. Dalla Pozza R, Beyerlein A, Thilmany C, Weissenbacher C, Netz H, et al. (2011) The effect of cardiovascular risk factors on the longitudinal evolution of the carotid intima medial thickness in children with type 1 diabetes mellitus. Cardiovasc Diabetol 10: 53.
24. Kuhnl A, Pelisek J, Tian W, Kuhlmann M, Rolland PH, et al. (2005) C-type natriuretic peptide inhibits constrictive remodeling without compromising re-endothelialization in balloon-dilated renal arteries. J Endovasc Ther 12: 171-182.
25. Wolf MB, Baynes JW, (2006) The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 1760: 267-271.
26. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, et al. (2010) Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 28: 166-172.
27. Bar-Joseph H, Ben-Aharon I, Tzabari M, Tsarfaty G, Stemmer SM, et al. (2011) In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One 6 (9): e23492 Epub 2011 Sep 9.
28. Murata T, Yamawaki H, Yoshimoto R, Hori M, Sato K, et al. (2001) Oct 19 Chronic effect of doxorubicin on vascular endothelium assessed by organ culture study. Life Sci. 69 (22): 2685-95.
29. Chan J, Prado-Lourenco L, Khachigian LM, Bennett MR, Di Bartolo BA, et al. (2010) TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappa B-dependent manner. Circ Res 106: 1061-1071.
30. Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TC, et al. (1995) Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 14: 632-639.
31. Ueno H, Kanellakis P, Agrotis A, Bobik A, (2000) Blood flow regulates the development of vascular hypertrophy, smooth muscle cell proliferation, and endothelial cell nitric oxide synthase in hypertension. Hypertension 36: 89-96.